Last updated: 11/07/2018 18:13:36
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -
Trial description: This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in Parkinson's Disease patients.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Food effects on Cmax and Cmin of SKF101468 (ropinirole) and its metabolites
Timeframe: Weeks 5-16
Food effects on AUC0-24 of SKF101468 (ropinirole) and its metabolites
Timeframe: Weeks 5-16
Food effects on tmax of SKF101468 (ropinirole) and its metabolites
Timeframe: Weeks 5-16
Plasma Trough Concentrations of SKF101468 (ropinirole) and its metabolites
Timeframe: Weeks 1-16
Secondary outcomes:
Total score in the Japanese UPDRS Part III
Timeframe: Weeks 0-52
Change from baseline in the Japanese UPDRS Part III
Timeframe: Baseline (Week 0) and Weeks 1-52
Percent Change from baseline in the Japanese UPDRS Part III
Timeframe: Baseline (Week 0) and Weeks 1-52
Percentage of responders of the total score in the Japanese UPDRS total score in Part III
Timeframe: Baseline (Week 0) and Weeks 1-52
Total score in the Japanese UPDRS Part I
Timeframe: Weeks 0-52
Change from baseline in the Japanese UPDRS Part I
Timeframe: Baseline (Week 0) and Weeks 1-52
Percent Change from baseline in the Japanese UPDRS Part I
Timeframe: Baseline (Week 0) and Weeks 1-52
Total score in the Japanese UPDRS Part II
Timeframe: Weeks 0-52
Change from baseline in the Japanese UPDRS Part II
Timeframe: Baseline (Week 0) and Weeks 1-52
Percent Change from baseline in the Japanese UPDRS Part II
Timeframe: Baseline (Week 0) and Weeks 1-52
Total score in the Japanese UPDRS Part IV
Timeframe: Baseline (Week 0) and Weeks 0-52
Change from baseline in the Japanese UPDRS Part IV
Timeframe: Baseline (Week 0) and Weeks 1-52
Percent Change from baseline in the Japanese UPDRS Part IV
Timeframe: Baseline (Week 0) and Weeks 1-52
Summary of the Modified Hoehn & Yahr criteria stages
Timeframe: Screening-Week 52
Number of participants scored as responders on the Clinician's global impression (CGI) scale
Timeframe: Weeks 1-52
Percentage of participants who remained in the study on the indicated days
Timeframe: Days 0-364
Change from baseline in albumin, total protein, and hemoglobin at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase, gamma glutamyl transferase, and lactate dehydrogenase at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in total bilirubin, blood urea nitrogen, and creatinine at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in blood urea nitrogen, cholesterol, chloride, potassium, and sodium at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in prolactin at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in hematocrit at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in platelet count and white blood cell count at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in red blood cell count at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Urinalysis Data
Timeframe: Screening, Week 16, and Week 52
Number of participants with the indicated shift from baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in supine and standing systolic and diastolic blood pressure at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Change from baseline in supine and standing pulse rate at Weeks 16 and 52
Timeframe: Baseline (Screening) and Weeks 16 and 52
Interventions:
Drug: Ropinirole prolonged release/extended release(PR/XR)
Enrollment:
62
Observational study model:
Not applicable
Primary completion date:
2009-10-03
Time perspective:
Not applicable
Clinical publications:
Nobutaka Hattori, Kazuko Hasegawa, Takashi Sakamoto. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson’s disease. J Clin Pharm Ther. 2012;37(5):571-577.
Medical condition
Parkinson Disease
Product
ropinirole
Collaborators
Not applicable
Study date(s)
April 2007 to March 2009
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
No
- Patients who are diagnosed with PD with severity of the Modified Hoehn & Yahr staging at Stage I to III.
- Age: 20 years or older (at the time of giving informed consent)
- Patients who present serious physical signs and symptoms other than those of the PD (e.g. cardiac/hepatic/renal disorder and haematopoietic disorder). The seriousness refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences (Pharmaceutical affairs bureau/Safety division (PAB/SD) Notification No. 80, dated 29 June 1992).
- Patients with symptomatic postural hypotension. (e.g. dizziness and syncope).
Inclusion and exclusion criteria
Inclusion criteria:
- Patients who are diagnosed with PD with severity of the Modified Hoehn & Yahr staging at Stage I to III.
- Age: 20 years or older (at the time of giving informed consent)
- Gender: male and female
- Both inpatient and outpatient status
- Informed consent: Patients who are able to give informed written consent in person (i.e. patients who are capable of giving informed written consent on one's own)
- Limited prior exposure to low or moderate doses of L-dopa (up to 3 months in total) or dopamine agonists (up to 6 months in total) provided treatment is discontinued for a minimum of 4 weeks prior to screening.
Exclusion criteria:
- Patients who present serious physical signs and symptoms other than those of the PD (e.g. cardiac/hepatic/renal disorder and haematopoietic disorder). The seriousness refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences (Pharmaceutical affairs bureau/Safety division (PAB/SD) Notification No. 80, dated 29 June 1992).
- Patients with symptomatic postural hypotension. (e.g. dizziness and syncope).
- Patients who have had serious psychiatric symptoms (e.g. confusion, hallucination, delusion, abnormal behaviour, alcohol or drug dependence) during the past six months (26 weeks) (including symptoms caused by anti-Parkinson drugs).
- Anticholinergic agents: trihexyphenidyl hydrochloride (e.g. Artane®), piroheptine hydrochloride (Trimol®), mazaticol hydrochloride (Pentona®), metixene hydrochloride (Cholinfall®), biperiden hydrochloride (Akineton®), profenamine (Parkin®)
- amantadine hydrochloride (e.g. Symmetrel®)
- droxidopa (Dops®)
- citicoline (e.g. Nicholin®)
- selegiline hydrochloride (FP®)
- zonisamide
- estrogen: estriol (e.g.Estriel®)
- CYP1A2 inhibitors: Ciprofloxacin HCl (e.g. Ciproxan®, enoxacin and fluvoxamine)
- Patients with severe dementia such as score 3 or 4 of the UPDRS Part I (Mentation, behaviour, and mood)
- Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study or within 30 days after the last dose of the study drug.
- Patients with current history or complication of carcinoma or malignant tumour.
- Patients who have history of drug allergy to ropinirole hydrochloride (HCl).
- Patients who have received surgical treatment for PD in the past (e.g. pallidectomy, deep brain stimulation).
- Patients who have been treated with any other investigational drug within 12weeks prior to the treatment phase.
- Others whom the investigator (sub investigator) considers ineligible for the study.
Patients who have been treated with the following drugs at Week -4, and whose treatment regimen of the drug has been changed from Week -4 to Week 0.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2009-10-03
Actual study completion date
2009-10-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website